Two U.S. healthcare systems, Tufts Medicine and University of Utah Health, will implement the DAC-SP Early Detection Blueprint across ten primary care sites to improve early detection of cognitive impairment and Alzheimer's disease. The initiative aims to refine a replicable model for early detection that can be adopted nationwide.
The Davos Alzheimer's Collaborative and Science for Africa Foundation are launching an initiative to harness artificial intelligence for brain health across Africa. The collaboration aims to transform prevention, diagnosis, and care for dementia and related brain health conditions through AI-driven solutions.
The Davos Alzheimer's Collaborative has launched a five-year plan to strengthen brain health in Africa and beyond, focusing on prevention and economic resilience. The six priorities of the 6x5 Plan include building resilient systems that support lifelong brain health and addressing cardiometabolic and lifestyle factors.
The Davos Alzheimer's Collaborative will present significant new research on early detection, diagnosis, and treatment, with a focus on expanding its research footprint across five continents. The initiative aims to translate science into real-world impact by building healthcare system capacity globally.
The Davos Alzheimer's Collaborative has partnered with PacBio to advance Alzheimer's disease research in North Africa. The collaboration aims to develop a comprehensive multi-omics dataset to better understand the genetics of Alzheimer's disease and dementia in diverse global populations.
The Brain Health Navigator program aims to provide resources for patients and providers at six US sites, promoting intuitive care navigation. The initiative supports healthcare providers across multiple settings, including frontline interactions and diagnosis, with educational components on brain health and post-diagnostic care.
The Davos Alzheimer's Collaborative is partnering with Janssen Research & Development and Beckman Coulter Diagnostics to advance the validation of blood-based biomarkers (BBMs) for Alzheimer's disease. This collaboration aims to develop globally generalizable blood tests that can be used in diverse populations, including those from low...
A recent study presented at the Future of Dementia in Africa conference reveals genetic differences between African and Caucasian populations with Alzheimer's disease. The findings suggest that a lack of diversity in genomic studies may limit the effectiveness of targeted therapies across diverse populations.